Use and outcomes of subcutaneous implantable cardioverter-defibrillator (ICD) after transvenous ICD extraction: An analysis of current clinical practice and a comparison with transvenous ICD reimplantation.


Journal

Heart rhythm
ISSN: 1556-3871
Titre abrégé: Heart Rhythm
Pays: United States
ID NLM: 101200317

Informations de publication

Date de publication:
04 2019
Historique:
received: 22 08 2018
pubmed: 27 10 2018
medline: 6 10 2020
entrez: 27 10 2018
Statut: ppublish

Résumé

The subcutaneous implantable cardioverter-defibrillator (S-ICD) does not require the insertion of any leads into the cardiovascular system. The aims of the study were to describe current practice and to measure outcomes associated with S-ICD or standard single-chamber transvenous ICD (TV-ICD) use after TV-ICD explantation. We analyzed all consecutive patients who underwent transvenous extraction of an ICD and subsequent implantation of an S-ICD or a single-chamber TV-ICD at 12 Italian centers from 2011 to 2017. A total of 229 patients were extracted and subsequently reimplanted with an S-ICD (90; 39%) or a single-chamber TV-ICD (139; 61%). S-ICD implantation increased from 9% in 2011 to 85% in 2017 (P < .001). Patients reimplanted with an S-ICD were younger (53 ± 13 years vs 60 ± 18 years; P = .011) and more frequently had undergone extraction owing to infection (73% vs 52%; P < .001). The rates of complications at follow-up were comparable between groups (hazard ratio 0.97; 95% confidence interval 0.49-1.92; P = .940). No lead failures, systemic infections, or system-related deaths occurred in the S-ICD group. In the TV-ICD group, 1 lead fracture occurred and 2 systemic infections were reported, resulting in death in 1 case. In the S-ICD group, the rate of complications was lower when the generator was positioned in a sub- or intermuscular pocket (hazard ratio 0.21; 95% confidence interval 0.05-0.87; P = .048). Our results show an increasing use of S-ICD over the years in patients undergoing TV-ICD explantation. An S-ICD is preferably adopted in young patients, mostly in the case of infection. The complication rate was comparable between groups and decreased when a sub- or intermuscular S-ICD generator position was adopted.

Sections du résumé

BACKGROUND
The subcutaneous implantable cardioverter-defibrillator (S-ICD) does not require the insertion of any leads into the cardiovascular system.
OBJECTIVE
The aims of the study were to describe current practice and to measure outcomes associated with S-ICD or standard single-chamber transvenous ICD (TV-ICD) use after TV-ICD explantation.
METHODS
We analyzed all consecutive patients who underwent transvenous extraction of an ICD and subsequent implantation of an S-ICD or a single-chamber TV-ICD at 12 Italian centers from 2011 to 2017.
RESULTS
A total of 229 patients were extracted and subsequently reimplanted with an S-ICD (90; 39%) or a single-chamber TV-ICD (139; 61%). S-ICD implantation increased from 9% in 2011 to 85% in 2017 (P < .001). Patients reimplanted with an S-ICD were younger (53 ± 13 years vs 60 ± 18 years; P = .011) and more frequently had undergone extraction owing to infection (73% vs 52%; P < .001). The rates of complications at follow-up were comparable between groups (hazard ratio 0.97; 95% confidence interval 0.49-1.92; P = .940). No lead failures, systemic infections, or system-related deaths occurred in the S-ICD group. In the TV-ICD group, 1 lead fracture occurred and 2 systemic infections were reported, resulting in death in 1 case. In the S-ICD group, the rate of complications was lower when the generator was positioned in a sub- or intermuscular pocket (hazard ratio 0.21; 95% confidence interval 0.05-0.87; P = .048).
CONCLUSION
Our results show an increasing use of S-ICD over the years in patients undergoing TV-ICD explantation. An S-ICD is preferably adopted in young patients, mostly in the case of infection. The complication rate was comparable between groups and decreased when a sub- or intermuscular S-ICD generator position was adopted.

Identifiants

pubmed: 30366163
pii: S1547-5271(18)31053-1
doi: 10.1016/j.hrthm.2018.10.026
pii:
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

564-571

Informations de copyright

Copyright © 2018 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.

Auteurs

Stefano Viani (S)

Second Cardiology Division, University Hospital of Pisa, Pisa, Italy. Electronic address: s.viani@ao-pisa.toscana.it.

Federico Migliore (F)

Department of Cardiac, Thoracic and Vascular Sciences, University of Padova, Padua, Italy.

Gianfranco Tola (G)

Cardiology Division, A.O. Brotzu, Cagliari, Italy.

Ennio C L Pisanò (ECL)

Vito Fazzi Hospital, Lecce, Italy.

Antonio Dello Russo (AD)

Centro Cardiologico Monzino IRCCS, Milan, Italy.

Giovanni Luzzi (G)

Cardiology Unit, University Hospital, Bari, Italy.

Paolo Sartori (P)

University Hospital IRCCS San Martino, Genoa, Italy.

Agostino Piro (A)

Policlinico Umberto I - "Sapienza" University of Rome, Rome, Italy.

Roberto Rordorf (R)

Department of Cardiology, Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy.

Giovanni Battista Forleo (GB)

Cardiology Department, Luigi Sacco Hospital, Milan, Italy.

Anna Rago (A)

Second University of Naples, Monaldi Hospital, Naples, Italy.

Luca Segreti (L)

Second Cardiology Division, University Hospital of Pisa, Pisa, Italy.

Emanuele Bertaglia (E)

Department of Cardiac, Thoracic and Vascular Sciences, University of Padova, Padua, Italy.

Mauro Biffi (M)

University of Bologna, Policlinico S.Orsola-Malpighi, Bologna, Italy.

Mariolina Lovecchio (M)

Boston Scientific, Milan, Italy.

Sergio Valsecchi (S)

Boston Scientific, Milan, Italy.

Igor Diemberger (I)

University of Bologna, Policlinico S.Orsola-Malpighi, Bologna, Italy.

Maria Grazia Bongiorni (MG)

Second Cardiology Division, University Hospital of Pisa, Pisa, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH